Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $302.00 price target on Biogen (NASDAQ: BIIB).The analyst commented: "At ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE